Our Business
Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and personal care products (including nutraceuticals and cosmeceuticals).
Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and Phosphagenics' ADR's (PPGNY) are traded on the OTCQX in the US.
Breaking News
29 June 2009
Phosphagenics Announces the Successful Completion of a Phase 1 Clinical Trial using TPM/Oxycodone
- Data demonstrates that repeat applications of TPM/oxycodone formulation does not cause significant opioid induced erythema or sensitisation
Phosphagenics Limited (“Phosphagenics”) (ASX: POH; OTCQX: PPGNY) today announced the successful completion of its Phase 1 Repeat Insult Patch Test (RIPT) demonstrating that the repeated application of its patented TPM/oxycodone formulation did not cause any significant erythema or sensitisation in humans.
To view the release in full please click here.
19 June 2009
Phosphagenics Signs Agreement with CSL to evaluate TPM technology
Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) today announced that it has signed a research and option agreement with global specialty biopharmaceutical company, CSL Limited (“CSL”).
The early stage research collaboration will focus on evaluating Phosphagenics’ proprietary TPM delivery technology to deliver large proteins.
To view the release in full please click here.
